This review examines how animal models predicted (or failed to predict) clinical trial outcomes for 16 Parkinson's drugs over the past 5 years, including multiple GLP-1 peptide agonists (exenatide, liraglutide, lixisenatide, semaglutide).
4 of 16 drugs reviewed are GLP-1 peptide agonistsExenatide, liraglutide, lixisenatide, and semaglutide represent the largest single drug class in this Parkinson's translation review — reflecting the enormous investment in GLP-1-based disease modification.
What the researchers found
The review covers 16 drugs that entered Parkinson's clinical trials after preclinical evaluation, across four categories: L-DOPA-induced dyskinesia treatment (buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant), parkinsonism treatment (tavapadon), disease modification (prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, semaglutide). For each drug, the review examines whether preclinical efficacy translated to clinical outcomes and identifies factors that influenced translational success or failure.
Why it matters
The extremely high failure rate of Parkinson's drugs in clinical trials (despite preclinical success) wastes billions in development costs and delays treatments for patients. Understanding why animal predictions fail — and specifically how GLP-1 peptide agonists are performing in this translation — is critical for the field. GLP-1 drugs represent the most exciting disease-modification candidates in Parkinson's, and this review contextualizes their clinical potential within the broader translation challenge.
How the study worked
Narrative review covering the past five years of Parkinson's disease drug development, examining 16 drugs from preclinical animal model testing through clinical trial outcomes. Each drug is analyzed for how well animal models predicted clinical efficacy, with discussion of model selection, design optimization, and translational barriers.
What this study cannot tell us
Narrative review focused primarily on the past five years, potentially missing earlier relevant data. The review covers translation from animal models to clinical trials but the clinical trials themselves are at various stages — not all have final results. The diverse mechanisms of the 16 drugs make direct comparisons of translational success difficult. The review primarily focuses on efficacy translation, with less attention to safety/tolerability translation failures.
How to read the evidence
This is a focused narrative review of drug translation from preclinical to clinical stages in Parkinson's disease. While it doesn't present original data, it provides valuable synthesis of how 16 drugs performed across the preclinical-clinical divide. The review is published in Current Opinion in Neurobiology, a respected journal for expert commentary.
When this study was published
Published in 2026, this is the most current review of Parkinson's drug translation, capturing the latest clinical trial data for GLP-1 agonists and other promising candidates.
The bigger picture
GLP-1 receptor agonists are generating unprecedented excitement for Parkinson's disease modification — semaglutide, liraglutide, and exenatide are all in clinical trials. This review places their development in the broader context of drug translation failures, providing valuable perspective on what animal data can and cannot tell us. The fact that 4 of 16 reviewed drugs are GLP-1 peptides reflects how central this drug class has become to Parkinson's research.
Questions still open
- Which GLP-1 agonist (exenatide, liraglutide, lixisenatide, or semaglutide) is showing the most promise in Parkinson's clinical trials?
- Can animal models of Parkinson's be redesigned to better predict disease modification — the hardest clinical endpoint to translate?
- Would patient selection based on biomarkers improve the clinical success rate for drugs that showed animal model efficacy?
Common questions
Are GLP-1 drugs like semaglutide being tested for Parkinson's disease?
Why do drugs that work in animal models of Parkinson's often fail in humans?
Read the original research
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease.
Current opinion in neurobiology, 97, 103164
Citation
Teil, Margaux; Huot, Philippe. (2026). The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease.. Current opinion in neurobiology, 97, 103164. https://doi.org/10.1016/j.conb.2025.103164